Anti-Myeloperoxidase Antibodies Associate with Future Proliferative Lupus Nephritis

Table 5

Temporal relationship of detectable autoantibodies. Patients without a clear antecedent antibody above the designated threshold were not included in analysis. OR, odds ratio; CI, confidence interval.

Comparison thresholds	Antecedent MPO-ANCA; (%)	Antecedent dsDNAab; (%)	OR	CI	value; (Fisher’s exact)
MPO-ANCA ≥ 3U/ml; versus; dsDNAab ≥ 3 IU/ml	89 (8/9)	11 (1/9)	64	3.4–1211	0.003
MPO-ANCA ≥ 3 U/ml versus; dsDNAab ≥ 5 IU/ml	100 (10/10)	0 (0/10)		5.5–	<0.001